4-溴-1H-吡咯并[2,3-B]吡啶-3-乙酸甲酯 | 1134327-78-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 4-溴-1H-吡咯并[2,3-B]吡啶-3-乙酸甲酯
• 英文名称: Methyl 2-(4-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)acetate
• 英文别名: methyl 2-(4-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)acetate
• CAS: 1134327-78-8
• 化学式: C₁₀H₉BrN₂O₂
• 分子量: 269.09
• InChiKey: RFXYTCVVADLKLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS
  申请人：CHIESI FARMACEUTICI S.P.A.

  公开号：US20180215758A1

  公开（公告）日：2018-08-02

  Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

  本文描述的式I的双环二氢嘧啶羧酰胺化合物抑制Rho激酶，可用于治疗与ROCK酶机制相关的许多疾病，如包括哮喘、慢性阻塞性肺疾病（COPD）、特发性肺纤维化（IPF）和肺动脉高压（PAH）在内的肺部疾病。
• Tyrosine amide derivatives as Rho-Kinase inhibitors
  申请人：CHIESI FARMACEUTICI S.P.A.

  公开号：US10954236B2

  公开（公告）日：2021-03-23

  Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

  本文所述式 I 的双环二氢嘧啶甲酰胺化合物可抑制 Rho 激酶，并可用于治疗与 ROCK 酶机制相关的多种疾病，如肺部疾病，包括哮喘、慢性阻塞性肺病 (COPD)、特发性肺纤维化 (IPF) 和肺动脉高压 (PAH)。
• [EN] TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE TYROSINE AMIDE UTILISÉS EN TANT QU'INHIBITEURS DE LA RHO-KINASE
  申请人：CHIESI FARM SPA

  公开号：WO2018138293A1

  公开（公告）日：2018-08-02

  The invention relates to compounds of formula (I) inhibiting Rho Kinase that are bicyclic dihydropyrimidine-carboxamide derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).